Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The respective “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the periods indicated - is as follows:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Numerator
Net loss - before noncontrolling interest	$	(12,670	)	$	(5,844	)	$	(22,779	)	$	(20,755	)
Net loss attributable to noncontrolling interest		1,199			266			1,877			702
Net loss - as reported, attributable to PAVmed Inc.	$	(11,471	)	$	(5,578	)	$	(20,902	)	$	(20,053	)
Series B Convertible Preferred Stock dividends:	$	(74	)	$	(71	)	$	(149	)	$	(141	)
Net loss attributable to PAVmed Inc. common stockholders	$	(11,545	)	$	(5,649	)	$	(21,051	)	$	(20,194	)
Denominator
Weighted average common shares outstanding, basic and diluted		82,235,397			44,780,538			78,117,637			44,140,126
Loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.14	)	$	(0.12	)	$	(0.27	)	$	(0.45	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.14	)	$	(0.13	)	$	(0.27	)	$	(0.46	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	June 30,
	2021		2020
PAVmed Inc. 2014 Equity Plan stock options and unvested restricted stock awards		10,573,530		7,965,195
Unit purchase options - as to shares of common stock		—		53,000
Unit purchase options - as to shares underlying Series Z Warrants		—		53,000
Series Z Warrants		15,074,281		16,815,039
Series W Warrants		381,818		381,818
Series B Convertible Preferred Stock(3)		1,185,685		1,179,872
Total		27,215,314		26,447,924